Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease.

Brain Commun · 2022 · PMC9683395 · PMID 36440097

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

an overall trendP = 0.076so close (0.05 < p ≤ 0.1)

Compared with placebo, there was an overall trend for better cognitive performance in the candesartan group reflected by the composite score (MD: 0.002, 95% CI: −0.0002, 0.005, P = 0.076).

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.